Overall Fundamental outlook

|fundrankingplaceholder|
|techrankingplaceholder|

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for DRREDDY
Revenue projections for DRREDDY

DRREDDY's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 1.802000
forwardPE 20.584564
debtToEquity 20.328000
earningsGrowth -0.862000
revenueGrowth -0.116000
grossMargins 0.527680
operatingMargins 0.052030
trailingEps 50.330000
forwardEps 64.509510

Dr. Reddy's Laboratories Limited's current ratio is 1.802, signaling that the company has sufficient cash reserves and current assets to cover its short-term debt obligations. This suggests financial stability, as Dr. Reddy's Laboratories Limited should not face any issues meeting its short-term liabilities with available resources.
With Dr. Reddy's Laboratories Limited's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
Dr. Reddy's Laboratories Limited's low Debt-to-Equity ratio indicates that the company isn't over-leveraged, suggesting it maintains a healthy balance between debt and equity. This lowers financial risk and points to a stable financial foundation, reassuring investors of the company's financial health.
DRREDDY's low earnings and revenue growth highlight a potential decline in profitability. This suggests that the company's financial health may be weakening, and profits could shrink as a result.
Dr. Reddy's Laboratories Limited's negative gross and operating margins signal that the company is not profitable, struggling to cover costs associated with production and operations. This could be a red flag for its financial performance moving forward.
Dr. Reddy's Laboratories Limited's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Dr. Reddy's Laboratories Limited's financial performance will improve in the current financial year.

Price projections:

Price projections for DRREDDY
Price projections for DRREDDY

The stock price of DRREDDY has frequently been close to the lower end of analysts' projections. This trend indicates potential struggles for the company in achieving the growth anticipated by the market.

Recommendation changes over time:

Recommendations trend for DRREDDY
Recommendations trend for DRREDDY


DRREDDY has recently received a buy bias from analysts, indicating that the stock is being perceived as a favorable investment. This positive sentiment could encourage investors to see DRREDDY as a wise place to allocate their funds, potentially leading to increased interest in the company's stock.